Norman N Kim

US Patent:

8455457, Jun 4, 2013

Filed:

Mar 18, 2011

Appl. No.:

13/051655

Inventors:

Norman N. Kim - Westford MA, US
William K. McVicar - Sudbury MA, US
Thomas G. McCauley - Cambridge MA, US

Assignee:

Inotek Pharmaceuticals Corporation - Lexington MA

International Classification:

A61K 31/70
A61K 31/41
A61K 31/12
A61K 31/075
A01N 43/04
A01N 43/82
A01N 35/00
A01N 31/14
C07H 19/167
C07H 19/173
C07D 285/12
C07D 285/14
C07D 417/00
C07D 513/00
C07C 39/12
C07C 39/06
C07C 39/18

US Classification:

514 46, 514363, 514677, 514718, 536 2762, 536 2763, 548141, 568734, 568780

Abstract:

Provided herein is a pharmaceutical composition or a kit comprising a combination of a non-selective beta-adrenergic receptor blocker and an adenosine Areceptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of timolol marketed under the brand Timoptic™ and Compound A.

US Patent:

8476247, Jul 2, 2013

Filed:

Mar 25, 2011

Appl. No.:

13/072349

Inventors:

Norman N. Kim - Westford MA, US
William K. McVicar - Sudbury MA, US
Thomas G. McCauley - Cambridge MA, US
Prakash Jagtap - N. Andover MA, US

Assignee:

Inotek Pharmaceuticals Corporation - Lexington MA

International Classification:

A61K 31/70
C07H 19/167
C07H 19/173

US Classification:

514 46, 536 2762

Abstract:

Provided herein is a method of reducing intraocular pressure (IOP) in humans using N6-cyclopentyladenosine (CPA), CPA derivatives or prodrugs or enhanced cornea permeability formulations of CPA. In one embodiment, the invention is directed to CPA derivatives or prodrugs that are permeable to the cornea. In another embodiment, the invention is directed to uses of certain compounds in human subjects for reducing and/or controlling elevated or abnormally fluctuating IOPs in the treatment of glaucoma or ocular hypertension (OHT).

US Patent:

20090005457, Jan 1, 2009

Filed:

Feb 21, 2008

Appl. No.:

12/070888

Inventors:

Michael Sizensky - South Grafton MA, US
Harold S. Wilkinson - Westborough MA, US
John Snoonian - Bolton MA, US
Norman Kim - Westford MA, US
Sharon M. Laughlin - Hudson MA, US
Roger P. Bakale - Downingtown MA, US
Kevin Plunkett - Walpole MA, US
Patrick Mousou - Granger IN, US

International Classification:

A61K 31/138
C07C 215/46
A61P 25/24
A61P 29/00
A61P 25/00
A61P 15/00

US Classification:

514653, 564443

Abstract:

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)—O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.

US Patent:

20110172177, Jul 14, 2011

Filed:

Jan 11, 2011

Appl. No.:

13/004380

Inventors:

Norman N. KIM - Westford MA, US
William K. MCVICAR - Sudbury MA, US
Thomas G. McCAULEY - Cambridge MA, US
Rudolf A. BAUMGARTNER - Sudbury MA, US

Assignee:

INOTEK PHARMACEUTICALS CORPORATION - Lexington MA

International Classification:

A61K 31/7076
A61K 31/216
A61K 31/19
A61K 31/165
A61P 27/02

US Classification:

514 46, 514530, 514573, 514622

Abstract:

The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor Aagonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan™ and Compound A.

US Patent:

20110245193, Oct 6, 2011

Filed:

Mar 18, 2011

Appl. No.:

13/051633

Inventors:

Norman N. KIM - Westford MA, US
William K. MCVICAR - Sudbury MA, US
Thomas G. MCCAULEY - Cambridge MA, US

Assignee:

INOTEK PHARMACEUTICALS CORPORATION - Lexington MA

International Classification:

A61K 31/7076
A61P 27/02
A61P 27/06

US Classification:

514 46

Abstract:

Provided herein is a pharmaceutical composition or a kit comprising a combination of a carbonic anhydrase inhibitor analog and an adenosine Areceptor agonist. Also provided herein is a method of reducing intraocular pressure (IOP) in a subject using such a combination or kit. In a particular embodiment, provided herein is a combination of dorzolamide marketed under the brand Trusopt™ and Compound A.

US Patent:

20160355457, Dec 8, 2016

Filed:

May 25, 2016

Appl. No.:

15/164394

Inventors:

- Marlborough MA, US
Harold S. Wilkinson - Westborough MA, US
John R. Snoonian - Bolton MA, US
Norman Kim - Westford MA, US
Sharon M. Laughlin - Hudson MA, US
Roger P. Bakale - Downington MA, US
Kevin Plunkett - Walpole MA, US
Patrick Mousaw - Rutland MA, US

International Classification:

C07C 215/64

Abstract:

Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, the invention provides solid forms comprising (−)-O-desmethylvenlafaxine, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, affective disorders such as depression, bipolar and manic disorders, attention deficit disorder, attention deficit disorder with hyperactivity, Parkinson's disease, epilepsy, cerebral function disorders, obesity and weight gain, incontinence, dementia and related disorders.